Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Proia

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Colorectal Cancer|December 3, 2014
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancerAndrea Cercek, Jinru Shia, Marc Gollub, et al.
International Journal of Oncology|November 16, 2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expressionSuqin He, Chaohua Zhang, Ayesha A Shafi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2018
Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell TumorsCheryl A London, Jaime Acquaviva, Donald L Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2013
Network analysis identifies an HSP90-central hub susceptible in ovarian cancerHanqing Liu, Fang Xiao, Ilya G Serebriiskii, et al.
Plos One|May 3, 2011
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signalingDavid A Proia, Kevin P Foley, Tim Korbut, et al.
Investigational New Drugs|January 10, 2012
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsDavid A Proia, Jim Sang, Suqin He, et al.
Oncoimmunology|April 9, 2016
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancerChristine Mall, Gail D Sckisel, David A Proia, et al.
Plos One|January 19, 2012
Mitochondrial electron transport is the cellular target of the oncology drug elesclomolRonald K Blackman, Kahlin Cheung-Ong, Marinella Gebbia, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney diseaseTamina Seeger-Nukpezah, David A Proia, Brian L Egleston, et al.
Molecular Cancer Research : MCR|May 3, 2014
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolismJaime Acquaviva, Suqin He, Chaohua Zhang, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Colorectal Cancer|December 3, 2014
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancerAndrea Cercek, Jinru Shia, Marc Gollub, et al.
International Journal of Oncology|November 16, 2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expressionSuqin He, Chaohua Zhang, Ayesha A Shafi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2018
Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell TumorsCheryl A London, Jaime Acquaviva, Donald L Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2013
Network analysis identifies an HSP90-central hub susceptible in ovarian cancerHanqing Liu, Fang Xiao, Ilya G Serebriiskii, et al.
Plos One|May 3, 2011
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signalingDavid A Proia, Kevin P Foley, Tim Korbut, et al.
Investigational New Drugs|January 10, 2012
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsDavid A Proia, Jim Sang, Suqin He, et al.
Oncoimmunology|April 9, 2016
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancerChristine Mall, Gail D Sckisel, David A Proia, et al.
Plos One|January 19, 2012
Mitochondrial electron transport is the cellular target of the oncology drug elesclomolRonald K Blackman, Kahlin Cheung-Ong, Marinella Gebbia, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney diseaseTamina Seeger-Nukpezah, David A Proia, Brian L Egleston, et al.
Molecular Cancer Research : MCR|May 3, 2014
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolismJaime Acquaviva, Suqin He, Chaohua Zhang, et al.
Pageof 5